Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Bloomage Biotechnology Corp., Ltd
Deal Size : Undisclosed
Deal Type : Termination
Medytox’s Chinese Partner Terminates BTX Deal
Details : Medytox applied for a license for Meditoxin (export name: Neuronox having Clostridium Botulinum Toxin type A), Medytox’s BTX product, to China’s National Medical Products Administration in February 2018.
Brand Name : Neuronox
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 04, 2022
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Bloomage Biotechnology Corp., Ltd
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : COVAX-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Vaxine
Deal Size : Undisclosed
Deal Type : Collaboration
Vaxine and Medytox partner on Covid-19 vaccine development
Details : The collaboration aims at developing a Covid-19 vaccine called, COVAX-19®, which is currently undergoing late stage animal testing and is based on Vaxine’s proprietary Advax™ adjuvant technology combined with a recombinant SARS-CoV-2 spike protein.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 25, 2020
Lead Product(s) : COVAX-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Vaxine
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
